Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan 1;60(1):134-141.
doi: 10.1093/jrr/rry091.

Clinical outcomes of hypofractionated image-guided multifocal irradiation using volumetric-modulated arc therapy for brain metastases

Shunsuke Furutani  1 , Hitoshi Ikushima  2 , Motoharu Sasaki  3 , Chisato Tonoiso  1 , Ayaka Takahashi  1 , Akiko Kubo  1 , Takashi Kawanaka  1 , Masafumi Harada  1
Affiliations

Clinical outcomes of hypofractionated image-guided multifocal irradiation using volumetric-modulated arc therapy for brain metastases

Shunsuke Furutani et al. J Radiat Res. .

Abstract

Volumetric-modulated arc therapy (VMAT) can be used to design hypofractionated radiotherapy treatment plans for multiple brain metastases. The purpose of this study was to evaluate treatment outcomes of hypofractionated image-guided multifocal irradiation using VMAT (HFIGMI-VMAT) for brain metastases. From July 2012 to December 2016, 67 consecutive patients with 601 brain metastases were treated with HFIGMI-VMAT at our institution. The prescribed dose was 50 Gy to a 95% volume of the planning target volume in 10 fractions. Fifty-five of the 67 patients had non-small-cell lung cancer, and the remaining 12 had other types of cancer. The median number of brain metastases was five, and the median maximum diameter was 1.2 cm. The median duration of follow-up was 12.0 months (range, 1.9-44.8 months), and the median survival time 18.7 months. Four patients with six lesions had local recurrences. The local control rate in the 64 assessed patients was 98.4% and 95.3% at 6 and 12 months, respectively (three died before assessment). The local control rate for the 572 assessed lesions was 99.8% and 99.3% at 6 and 12 months, respectively. Thirty-nine patients developed distant brain metastases, the distant brain control rate being 59.7% and 40.5% at 6 and 12 months, respectively. Acute toxicities were generally mild (Grade 1-2). Three patients (4.5%) developed radiation necrosis requiring corticosteroid therapy. The HFIGMI-VMAT technique with flat dose delivery was well tolerated and achieved excellent local control. This technique is a promising treatment option for patients with multiple and large brain metastases.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Local control achieved in the 64 assessed patients.
Fig. 2.
Fig. 2.
(a) Local control of 572 treated lesions. (b) Local control according to tumor diameter.
Fig. 3.
Fig. 3.
Distant brain control achieved in the 64 assessed patients.
Fig. 4.
Fig. 4.
Overall survival of all 67 patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Soffietti R, Ruda R, Mutani R. Management of brain metastases. J Neurol 2002;249:1357–69. - PubMed
    1. Tabouret E, Chinot O, Metellus P et al. . Recent trends in epidemiology of brain metastases: an overview. Anticancer Res 2012;32:4655–62. - PubMed
    1. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep 2011;14:48–54. - PubMed
    1. Lin JJ, Cardarella S, Lydon CA et al. . Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol 2016;11:556–65. - PMC - PubMed
    1. Nieder C, Spanne O, Mehta MP et al. . Presentation, patterns of care, and survival in patients with brain metastases. Cancer 2011;117:2505–12. - PubMed